Avvinity Therapeutics was founded as an immuno-oncology joint venture between Horizon Discovery and Centauri Therapeutics. In July 2020, following seed funding from LifeArc and the UK Government’s Future Fund, the company was granted full ownership of the Alphamer technology platform and became an independent biotech company. Avvinity is a virtual company with an experienced ex-Pfizer R&D team, which is supported by industry experienced consultants and contract research organisations. The company has an office at Discovery Park, Sandwich, Kent.
Avvinity is passionate about applying its Alphamer technology to develop novel immunotherapeutics that will not only address challenging solid and liquid tumours, but also prevent their recurrence. As targeted therapies, Alphamer based therapeutics also have the potential to avoid the suffering caused by the toxicities associated with many current cancer therapies.
The flexibility of the technology makes it amenable to partnering with other compounds for products to treat alternative disease areas and the team are keen to explore such opportunities with potential collaborators. Please get in touch using our contact details if you would like to discuss this further.